A promising scan may finally crack one of women’s health’s most stubborn delays: spotting endometriosis without sending patients to surgery first.
A trial involving 19 women suggests an experimental radiotracer called maraciclatide can make endometriosis “light up” on a scan, according to reports on the findings. That matters because endometriosis often takes years to identify, while symptoms disrupt work, education, relationships, and daily life. In England, women typically wait nearly a decade for a diagnosis, a gap that has long fueled frustration among patients and clinicians alike.
The early results suggest doctors may be able to detect endometriosis with a scan instead of relying so heavily on investigative surgery.
Right now, that surgical step remains a major bottleneck. Investigative procedures can slow diagnosis, raise costs, and add another hurdle for people already navigating pain and uncertainty. A reliable non-invasive scan would not just speed up answers; it could change how doctors triage symptoms, decide on treatment, and monitor the condition over time. Even at this early stage, the trial signals a possible shift from suspicion to clearer evidence.
Key Facts
- A trial of 19 women produced promising early results for a non-invasive endometriosis scan.
- The experimental radiotracer maraciclatide appears to help endometriosis show up on imaging.
- Current diagnosis often depends on investigative surgery, which can delay care.
- Women in England typically wait nearly a decade for an endometriosis diagnosis.
Caution still matters. The study is small, and early success does not guarantee a tool that works across the wide range of endometriosis cases seen in clinics. Researchers will need larger trials to show how accurately the scan detects the disease, where it performs best, and whether it can reduce missed cases or unnecessary procedures. Sources suggest those next steps will determine whether this remains a promising experiment or becomes a standard part of care.
What happens next could shape the future of diagnosis for millions of women. If bigger studies confirm the findings, maraciclatide-based imaging could move endometriosis care toward faster answers and earlier treatment. That would matter far beyond the scan itself: quicker diagnosis can mean less pain without explanation, fewer years lost in medical limbo, and a health system that responds faster when patients say something is wrong.